At the center of the debate are the growing number of manufacturer demands for claims data as a condition of 340B pricing.
|Articles|April 1, 2011
Drug Topics, Digital Edition, April 2011
The New Stability (2011 Style) 2011 Salary Survey : Wage levels strong, workloads and stress on the rise Dietary Supplements and Patient Counseling Confessions of a counter-detailer Hospital manages drugspend trends, boosts ROI Public health and ethnically diverse populations
Advertisement
Advertisement
Related to this article
Nicholas Rebold, PharmD, MPH, BCIDP, AAHIVP, discusses his team’s and patients’ experiences in a pharmacist-led antiretroviral initiative.
Zaid Fadul, MD, FS, FAAFP, introduces the Nolla Derm app, what it might mean for pharmacists and their patients, and where AI prescribing is headed in the future.
Among a collection of patients across 15 pharmacies, researchers assessed acceptability and satisfaction with pharmacist-led clinical services.
From expert sources and recent data updates to a look at cases amid the ongoing respiratory virus season, this is an updated look at 2026 measles outbreaks in the US.
Zaid Fadul, MD, FS, FAAFP, joins for part 2 to discuss what greater adoption of AI across health care ecosystems might mean for pharmacists, patients, and more.
For pharmacies competing with CVS and relying on Caremark to serve patients, the prospect of those businesses operating under separate ownership is significant.
Erin Albert of Mark Cuban Cost Plus Drugs explains how the Team Cuban Card offers transparent pricing and fair pay for independent pharmacies.
Advertisement
Advertisement